Overview

Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme

Status:
Withdrawn
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus carboplatin in treating patients who have recurrent glioblastoma multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carboplatin
Dacarbazine
Temozolomide